UNLABELLED: Previous studies have shown familial aggregation of insulin resistance and nonalcoholic fatty liver disease (NAFLD). Therefore, we aimed to examine whether family history of diabetes mellitus (DM) is associated with nonalcoholic steatohepatitis (NASH) and fibrosis in patients with NAFLD. This was a cross-sectional analysis in participants of the NAFLD Database study and PIVENS trial who had available data on family history of DM. One thousand and sixty-nine patients (63% women), with mean age of 49.6 (± 11.8) years and body mass index (BMI) of 34.2 (± 6.4) kg/m(2) , were included. Thirty percent had DM, and 56% had a family history of DM. Both personal history of DM and family history of DM were significantly associated with NASH, with an odds ratio (OR) of 1.93 (95% confidence interval [CI]: 1.37-2.73; P <0.001) and 1.48 (95% CI: 1.11-1.97; P = 0.01) and any fibrosis with an OR of 3.31 (95% CI: 2.26-4.85; P < 0.001) and 1.66 (95% CI: 1.25-2.20; P < 0.001), respectively. When the models were adjusted for age, sex, BMI, ethnicity, and metabolic traits, the association between diabetes and family history of DM with NASH showed an increased adjusted OR of 1.76 (95% CI: 1.13-2.72; P < 0.001) and 1.34 (95% CI: 0.99-1.81; P = 0.06), respectively, and with any fibrosis with a significant adjusted OR of 2.57 (95% CI: 1.61-4.11; P < 0.0001) and 1.38 (95% CI: 1.02-1.87; P = 0.04), respectively. After excluding patients with personal history of diabetes, family history of DM was significantly associated with the presence of NASH and any fibrosis with an adjusted OR of 1.51 (95% CI: 1.01-2.25; P = 0.04) and 1.49 (95% CI: 1.01-2.20; P = 0.04), respectively. CONCLUSIONS: Diabetes is strongly associated with risk of NASH, fibrosis, and advanced fibrosis. Family history of diabetes, especially among nondiabetics, is associated with NASH and fibrosis in NAFLD.
UNLABELLED: Previous studies have shown familial aggregation of insulin resistance and nonalcoholic fatty liver disease (NAFLD). Therefore, we aimed to examine whether family history of diabetes mellitus (DM) is associated with nonalcoholic steatohepatitis (NASH) and fibrosis in patients with NAFLD. This was a cross-sectional analysis in participants of the NAFLD Database study and PIVENS trial who had available data on family history of DM. One thousand and sixty-nine patients (63% women), with mean age of 49.6 (± 11.8) years and body mass index (BMI) of 34.2 (± 6.4) kg/m(2) , were included. Thirty percent had DM, and 56% had a family history of DM. Both personal history of DM and family history of DM were significantly associated with NASH, with an odds ratio (OR) of 1.93 (95% confidence interval [CI]: 1.37-2.73; P <0.001) and 1.48 (95% CI: 1.11-1.97; P = 0.01) and any fibrosis with an OR of 3.31 (95% CI: 2.26-4.85; P < 0.001) and 1.66 (95% CI: 1.25-2.20; P < 0.001), respectively. When the models were adjusted for age, sex, BMI, ethnicity, and metabolic traits, the association between diabetes and family history of DM with NASH showed an increased adjusted OR of 1.76 (95% CI: 1.13-2.72; P < 0.001) and 1.34 (95% CI: 0.99-1.81; P = 0.06), respectively, and with any fibrosis with a significant adjusted OR of 2.57 (95% CI: 1.61-4.11; P < 0.0001) and 1.38 (95% CI: 1.02-1.87; P = 0.04), respectively. After excluding patients with personal history of diabetes, family history of DM was significantly associated with the presence of NASH and any fibrosis with an adjusted OR of 1.51 (95% CI: 1.01-2.25; P = 0.04) and 1.49 (95% CI: 1.01-2.20; P = 0.04), respectively. CONCLUSIONS:Diabetes is strongly associated with risk of NASH, fibrosis, and advanced fibrosis. Family history of diabetes, especially among nondiabetics, is associated with NASH and fibrosis in NAFLD.
Authors: Rohit Loomba; Fangwen Rao; Lian Zhang; Srikrishna Khandrika; Michael G Ziegler; David A Brenner; Daniel T O'Connor Journal: Gastroenterology Date: 2010-06-09 Impact factor: 22.682
Authors: Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Naga P Chalasani; Arun J Sanyal; Kris V Kowdley; Patricia R Robuck; Jay Hoofnagle; David E Kleiner; Aynur Unalp; James Tonascia Journal: Contemp Clin Trials Date: 2008-09-10 Impact factor: 2.226
Authors: Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri Journal: Hepatology Date: 2011-02-11 Impact factor: 17.425
Authors: Lynne E Wagenknecht; Ann L Scherzinger; Elizabeth R Stamm; Anthony J G Hanley; Jill M Norris; Yii-Der I Chen; Michael Bryer-Ash; Steven M Haffner; Jerome I Rotter Journal: Obesity (Silver Spring) Date: 2009-02-19 Impact factor: 5.002
Authors: Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner Journal: Gastroenterology Date: 2015-08-20 Impact factor: 22.682
Authors: T Filardi; F Panimolle; C Tiberti; C Crescioli; A Lenzi; N Pallotta; S Morano Journal: J Endocrinol Invest Date: 2020-04-30 Impact factor: 4.256